HIV

J&J Ends Mosaico HIV Vaccine Trial on poor Results

Johnson & Johnson’s pharmaceuticals subsidiary Janssen is walking away from plans to launch an HIV vaccine in the immediate future after the data safety monitoring board for its latest Phase 3 trial found that the shot was no better than a placebo.

Gilead HIV Pill Seen to Lower new Infections

FDA Approves new Two-drug HIV Treatment

Abivax and PCAS Collaborate on HIV/Aids Drug

Gilead‘s Genvoya HIV Treatment gets FDA Approval

GSK Outlines Pipeline for Next 10 Years

The Future Lies in the Genome

Bristol-Myers Squibb HIV Drug Fast-Tracked

Carlyle Wins J&J Diagnostic Unit

GSK Raises Bet on AIDS Drug with New Shionogi Deal